• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Surgeons Successfully Replace Aortic Valve in Rare Neurofibromatosis Type 1 Case

by
November 17, 2026
in Health
Reading Time: 6 mins read
0
Surgeons Successfully Replace Aortic Valve in Rare Neurofibromatosis Type 1 Case

Surgeons Successfully Replace Aortic Valve in Rare Neurofibromatosis Type 1 Case

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

In a case report published in the Journal of Rare Diseases, surgeons detailed the surgical management and perioperative considerations for a 67-year-old woman with neurofibromatosis type 1 who developed severe aortic regurgitation. Although neurofibromatosis type 1 is a well-described genetic disorder, clinically significant valvular disease requiring cardiac surgery is rarely reported. The patient presented with progressive exertional dyspnea of New York Heart Association functional class III, orthopnea, and palpitations lasting six months. After evaluation diagnosed severe aortic regurgitation with left ventricular dilatation, she underwent multidisciplinary assessment to address cardiac surgery risks in this multisystem disorder. Her successful bioprosthetic aortic valve replacement highlights valuable clinical insights into managing potential vascular fragility, occult arterial stenosis, and unique perioperative challenges in neurofibromatosis type 1.

Neurofibromatosis type 1 is an autosomal dominant disorder caused by mutations in the NF1 gene on chromosome 17q11.2, affecting roughly 1 in 3,000 births. It is an inherited tumor-predisposition condition characterized clinically by café-au-lait macules, axillary or inguinal freckling, neurofibromas, Lisch nodules, skeletal abnormalities, and an increased risk of neoplasms. Consensus nomenclature distinguishes it from conditions historically called neurofibromatosis type 2, now classified within the schwannomatosis spectrum as NF2-related schwannomatosis on chromosome 22q12, alongside SMARCB1-related and LZTR1-related forms. In neurofibromatosis type 1, neurofibromin regulates Ras-dependent signaling and vascular homeostasis. Its expression in vascular endothelial and smooth muscle cells provides a biological explanation for vascular lesions, including renal artery stenosis, aneurysmal dilatation, and arterial dissection.

Cardiovascular involvement in neurofibromatosis type 1 encompasses diverse vascular and congenital cardiac anomalies, including renal artery stenosis, midaortic syndrome, hypertension, pulmonary stenosis, septal defects, aortic stenosis, mitral abnormalities, and hypertrophic cardiomyopathy. Pediatric imaging cohorts report congenital cardiac malformations in up to 27 percent of patients, occurring more frequently in those harboring large NF1 microdeletions than in individuals with intragenic variants. Despite these recognized cardiovascular features, acquired valvular disease requiring operative repair remains exceedingly uncommon in the adult population. Previous literature contains isolated reports of atypical valve morphologies, such as quadricuspid aortic valves or severe regurgitant lesions without infective or rheumatic causes. Because published clinical data are sparse, researchers emphasize that existing evidence cannot determine whether adult aortic regurgitation represents an authentic biological complication of neurofibromin deficiency or an incidental age-related degeneration.

The patient’s initial physical examination demonstrated how widespread neurocutaneous manifestations can impede conventional bedside cardiovascular assessment. Multiple cutaneous neurofibromas and café-au-lait macules covered her body, without gross neurocognitive deficits or overt spinal deformities. Cardiovascular examination detected a collapsing pulse, wide pulse pressure, and a decrescendo diastolic murmur along the left sternal border. However, manual blood pressure measurement was severely limited and painful because compressing extensive cutaneous neurofibromas with an inflatable cuff caused marked discomfort. Blood pressure measurements across the four limbs revealed 104/43 mmHg in the right upper limb, 122/54 mmHg in the left upper limb, 135/56 mmHg in the right lower limb, and 138/55 mmHg in the left lower limb. This notable inter-arm discrepancy was ultimately linked to occult right subclavian artery stenosis, illustrating that physical findings in neurofibromatosis type 1 must be interpreted alongside objective vascular imaging.

Diagnostic investigations established the severity of cardiac dysfunction while evaluating the arterial tree for systemic vascular complications. Electrocardiography demonstrated left ventricular hypertrophy with normal sinus rhythm. Transthoracic echocardiography confirmed severe aortic regurgitation with left ventricular dilatation, showing a left ventricular internal diameter in systole and diastole of 50 and 70 millimeters, a pressure half-time of 180 milliseconds, and an ejection fraction of 50 to 55 percent. Coronary angiography demonstrated no obstructive coronary artery disease. Computed tomography of the chest and abdomen revealed a dilated ascending aorta measuring 45 by 46 millimeters, without dissection or focal lesions, and excluded adrenal masses. Abdominal ultrasonography and Doppler studies showed normal renal and carotid vessels, but right vertebral artery Doppler imaging detected systolic flow deceleration with preserved antegrade flow, verifying occult right subclavian stenosis. Because the patient had no upper-limb ischemic symptoms, active intervention for subclavian stenosis was deferred with routine monitoring.

Given the multisystem nature of neurofibromatosis type 1, focused preoperative consultations with general medicine and endocrinology identified potential perioperative hazards. A critical priority was ruling out pheochromocytoma, a rare catecholamine-secreting tumor that can provoke catastrophic perioperative hypertensive crises and severe hemodynamic instability. Unrecognized pheochromocytoma also poses severe risks because post-valve-replacement regimens commonly include beta-blockers, which can trigger hypertensive crises through unopposed alpha-adrenergic stimulation. The patient exhibited no clinical features of pheochromocytoma, such as unprovoked tachycardia, episodic sweating, severe headaches, or uncontrolled hypertension, and thoraco-abdominal imaging showed normal adrenal glands. Following endocrine consultation, biochemical metanephrine testing was omitted. Preoperative planning also considered radiation risks, as individuals with neurofibromatosis type 1 may exhibit enhanced susceptibility to ionizing radiation and secondary malignancies; clinicians therefore avoided unnecessary diagnostic radiation such as brain computed tomography. Furthermore, invasive arterial line monitoring was intentionally avoided in the right upper limb due to subclavian stenosis.

The choice of prosthetic valve was individualized through shared decision-making, balancing long-term hemodynamic performance against the distinctive biological complications of neurofibromatosis type 1. Under 2025 European Society of Cardiology and European Association for Cardio-Thoracic Surgery guidelines, prosthetic valve selection follows a patient-centered approach, with age over 65 carrying a Class IIa recommendation for a bioprosthetic valve. Selecting a mechanical valve would have necessitated lifelong oral anticoagulation, introducing considerable bleeding hazards in a patient with potential tissue and vascular fragility. Although neurofibromatosis type 1 is not a primary bleeding disorder, bleeding complications have been documented in connection with vascular fragility, von Willebrand factor deficiency, and hemorrhage from plexiform neurofibromas. Moreover, regular anticoagulant monitoring and dosage titration posed significant logistical and financial difficulties for the patient, who resided in a remote geographic region. After considering these factors and patient preference, the clinical team selected a bioprosthetic aortic valve.

A key surgical consideration involved deciding whether to perform concomitant ascending aortic replacement alongside valve surgery. Preoperative computed tomography showed symmetrical dilatation of the aortic root and sinuses measuring approximately 40 millimeters, with the ascending aorta measuring 42 millimeters proximally, 45 to 46 millimeters mid-portion, and 42 to 43 millimeters distally, yielding an aortic size index of 2.7 cm/m² and an aortic height index of 2.78 cm/m. Aortic guidelines suggest concomitant aortic surgery can be considered during valve replacement when the ascending aorta reaches 45 millimeters or more, representing a Class IIa recommendation based on Level C evidence. In this patient, the aortic valve was tricuspid, no dissection or focal pathology existed, dilatation was symmetrical, and indexed dimensions did not indicate high risk. To avoid unnecessary operative complexity, the team decided against aortic replacement, counseling the family and preparing to intervene intraoperatively if aortic wall thinning or fragility was encountered.

The surgical procedure was performed through a median sternotomy with bicaval venous cannulation, chosen to maintain surgical options if aortic reconstruction proved necessary. Intraoperatively, the aortic root, sinuses, and ascending aorta were symmetrically dilated, but the aortic wall appeared adequately thick and of satisfactory tissue quality. Transverse aortotomy revealed a tricuspid aortic valve with thickened, retracted cusps and central regurgitation, without commissural fusion, calcification, or vegetations suggestive of rheumatic or infective pathology. Sternal bone quality appeared somewhat reduced, attributed to age or nutritional factors. The patient received a 21-millimeter bioprosthetic valve secured with non-pledgeted 2-0 Ethibond sutures placed intra-annularly, and the aortotomy was closed in two layers with polypropylene sutures without tissue injury or bleeding. Cardiopulmonary bypass and aortic cross-clamp times were 80 and 55 minutes, respectively, maintaining mean arterial pressure at 50 to 60 mmHg. Baseline intraoperative activated clotting time was 150 seconds, and postoperative drain output was 170 milliliters over the first 24 hours.

The patient experienced an uneventful postoperative recovery and was discharged on postoperative day five. Transesophageal echocardiography confirmed a well-seated, properly functioning prosthetic valve, while electrocardiography demonstrated stable normal sinus rhythm. In the intensive care unit, blood pressure was strictly controlled to avoid sudden elevations that could compromise aortic integrity, and no arrhythmias or bleeding complications developed. Histopathological examination of the excised leaflets confirmed non-specific degenerative changes without intracardiac fibroma or myxomatous tissue. At a ten-day follow-up, the surgical incision was healing satisfactorily with a stable sternum and resolved symptoms. At one year of follow-up, the patient remained clinically well, with echocardiography demonstrating a normally functioning bioprosthesis, preserved left ventricular ejection fraction of 55 percent, and reverse ventricular remodeling with reduced diameters of 45 millimeters in systole and 64 millimeters in diastole.

This clinical experience highlights broader management considerations for patients with neurofibromatosis type 1 undergoing major cardiovascular surgery. Postoperative pharmacological management requires vigilance; for example, angiotensin-converting enzyme inhibitors, commonly prescribed following aortic valve replacement, should be administered only after renal artery stenosis has been excluded, as unrecognized stenosis can severely complicate blood pressure control. Similarly, beta-blocker therapy must be withheld until pheochromocytoma has been definitively ruled out. Physical examination findings in this population should always be corroborated with objective cross-sectional and vascular imaging, given the confounding effects of cutaneous neurofibromas and subclinical vascular stenoses. Although this single case report cannot determine whether aortic regurgitation and ascending aortic dilatation were caused by neurofibromin-mediated vasculopathy or coincidental age-related degeneration, it reinforces the International NF1 Cardiovascular Taskforce consensus advocating systematic, multidisciplinary cardiovascular surveillance and individualized perioperative planning to achieve optimal surgical outcomes.

Subject of Research: Surgical aortic valve replacement and perioperative management in neurofibromatosis type 1

Article Title: Aortic valve replacement in a patient with neurofibromatosis type 1: surgical considerations and perioperative management

Article References: Kar, T., Bansal, A., & Singhal, A. (2026). Aortic valve replacement in a patient with neurofibromatosis type 1: surgical considerations and perioperative management. Journal of Rare Diseases, 5(1), Article 108. https://doi.org/10.1007/s44162-026-00251-w

Image Credits: AI Generated

DOI: 10.1007/s44162-026-00251-w

Keywords: neurofibromatosis type 1, aortic valve replacement, aortic regurgitation, bioprosthetic valve, ascending aorta dilatation, subclavian artery stenosis, perioperative management, cardiac surgery, neurofibromin, pheochromocytoma screening, vasculopathy, transthoracic echocardiography, cardiopulmonary bypass, NF1 gene, cutaneous neurofibromas, tissue fragility, Journal of Rare Diseases, International NF1 Cardiovascular Taskforce

News Source: Ophelia Keating. (November 17, 2026). Surgeons Successfully Replace Aortic Valve in Rare Neurofibromatosis Type 1 Case. Scienmag.

Tags: aortic regurgitationaortic valve replacementascending aorta dilatationbioprosthetic valveCardiac Surgerycardiopulmonary bypasscutaneous neurofibromasInternational NF1 Cardiovascular TaskforceJournal of Rare Diseasesneurofibromatosis type 1NeurofibrominNF1 geneperioperative managementpheochromocytoma screeningsubclavian artery stenosistissue fragilitytransthoracic echocardiographyvasculopathy
Share12Tweet7Share2ShareShareShare1

Related Posts

Preoperative Temporal Muscle Thickness Predicts Recovery After Chronic Subdural Hematoma Surgery

Preoperative Temporal Muscle Thickness Predicts Recovery After Chronic Subdural Hematoma Surgery

November 17, 2026
Review Links Occupational Trauma to Severe Functional and Return-to-Work Impairments

Review Links Occupational Trauma to Severe Functional and Return-to-Work Impairments

November 17, 2026

Cardiovascular Disease Significantly Increases Economic and Humanistic Burden in Kidney Failure

November 17, 2026

Thai Hypertension Study Reveals Shifts in Cardiovascular Risk Factors, 2011–2018

November 17, 2026

POPULAR NEWS

  • Pharmacist Prescribing for Urinary Tract Infections Shows High Symptom Resolution

    Pharmacist Prescribing for Urinary Tract Infections Shows High Symptom Resolution

    29 shares
    Share 12 Tweet 7
  • Bioactive Adrenomedullin Rises During Hemorrhagic Shock and Stabilizes With Fluid Resuscitation

    29 shares
    Share 12 Tweet 7
  • Serious Gaming Platform Validated for Basic Laparoscopic Skills Training

    29 shares
    Share 12 Tweet 7
  • Anti-Aging Drugs Show Sex-Specific Interleukin-11 Effects in Mouse Abdominal Fat

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Preoperative Temporal Muscle Thickness Predicts Recovery After Chronic Subdural Hematoma Surgery

Review Links Occupational Trauma to Severe Functional and Return-to-Work Impairments

Optimization Model Compresses Construction Schedules to Sixty-Two Days Under Periodic Budget Caps

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.